linkedin.com/pulse/guide-you… Please check out this article meant to help #RTTs in their first five years. @OfficialRCCSInc @ASRT @RegentsHealth #radiationtherapy

Our CEO always enjoys working with Residents. Every specialty can benefit from the business side of Healthcare

AI is already here in how we prognosticate mHSPC. One biopsy-based score, validated in two RPh3 trials: 📉 5-yr prostate cancer death, low-volume (STAMPEDE): 27% with a low score → 43% with a high score 📈 5-yr overall survival (CHAARTED): 83% with a low score → 39% with a high score 🎯 Prognostic, and not predictive yet #ProstateCancer #mHSPC #AIinMedicine #GUonc #AIinOncology

New in #practicalRO: Clinical Heterogeneity and Risk Stratification of Carotid Blowout Syndrome After Definitive Radiation Therapy for Nasopharyngeal Carcinoma. tinyurl.com/proqytan

We are so excited that City of Hope has broken ground on the Pathology and Radiation Oncology Building, which will serve as the new home for our department in the near future as a means for us to continue to provide innovative radiation treatments.

It has been my great pleasure and honor to serve as the Scientific Program Co-Chair and Clinical Leading Chair for PTCOG for the past four years. I am delighted to witness the advancement of cutting-edge radiation therapy technology and the growth of our talented young colleagues. This will be my last time presenting the Dr. Michael Goitein Award to our outstanding clinical young investigator. @BrianDeMD @PTCOG_Official

Long-term survival for patients with newly-diagnosed metastatic cancer has more than doubled ⏫ in the past 40 years.

💡🚀 New webinar series: Business of Radiation Oncology with @DigiaimoRon and 2 of our ARRO members. This highlights reimbursement, billing codes, and considerations for your first job📊 Watch Now tiny.cc/fsk4101 🎥🍿

This was a productive series that hopefully helps many Current and future Rad Oncs across the country! It was a lot of fun and engaging. It will be exciting to follow so many careers that will develop our future specialty 👍🏻👊🏻👏🏻 @OfficialRCCSInc

ATTN Physicians and Americans: Remember the hit piece against physicians and their salaries in USA Today??? Well, the highest-paid insurance executives in the United States primarily lead major health and Property & Casualty (P&C) organizations. Executive compensation is heavily weighted toward stock awards and incentives, rather than base salaries. Top executives from recent proxy filings: Andrew Witty: CEO of UNITEDHEALTH Group. Recognized as the highest-paid payer CEO, his total compensation reached $26.3 million. Evan Greenberg: Chairman & CEO of Chubb. Leading a massive P&C firm, his total compensation was over $27.6 million, with some industry evaluations placing his adjusted compensation even higher at $30.1 million. Nicolas Papadopoulo: Executive at Arch Capital. He is among the highest-paid P&C leaders with adjusted compensation reported near $31.7 million. David Cordani: CEO of CIGNA Group. He consistently ranks near the top with a total compensation of $23.25 million (and has historically seen total packages over $91 million during high-vesting periods). Thomas Wilson: CEO of Allstate. He features prominently as one of the highest-paid leaders in personal lines, with adjusted compensation over $26 million.Joseph Zubretsky: CEO of Molina Healthcare. He rounds out the top healthcare leaders with compensation packages of approximately $21.9 million. Peter Zaffino: Chairman & CEO of AIG. He typically earns around $24.6 million in total compensation.

Absolutely YES: healthcaredive.com/news/amer…

If I was a patient? Yes, but I’d also want a particular treatment, particular staff and a particular Rad onc with the consultation of many friends…. But that’s just me…. 😁

Thank you so much to @advocatehealth @AtriumHealth and @LevineCancer Center for the invitation to speak on Radiation Oncology and Medical Oncology finance and reimbursement. Super engaged team and a fun time (at least as much fun as the topic can be haha)👍🏻👊🏻@OfficialRCCSInc

In a retrospective cohort of 68 DLBCL patients with partial metabolic response on interim PET after 4 cycles of R-CHOP, PET-directed residual site RT was associated with improved response and PFS. 29 patients received additional R-CHOP risk-adapted pRSRT: • Deauville 4: 24 Gy • Deauville 5: 40 Gy Compared with no RT, pRSRT improved EOT CR: • Overall: 72.4% vs 41.0% • Deauville 5 subgroup: 83.3% vs 22.2% PFS also favored pRSRT: • 2-year PFS: 85.8% vs 52.9% • 5-year PFS: 57.2% vs 44.1% • Multivariable HR 0.26, p=0.018 No statistically significant OS difference was observed, with limited events and no deaths in the RT cohort. Toxicity was generally manageable, though one grade 4 bowel perforation occurred. Although this cohort was treated in the R-CHOP era, the question remains highly relevant in the POLARIX/pola-R-CHP era: when residual PET-avid disease persists despite improved systemic therapy, PET-directed RT may still have a role as a selective consolidation strategy. #lymsm #DLBCL #OncTwitter

Thank you so much to @FoxChaseCancer and @TempleUniv for the invitation to present and speak on Radiation Oncology finance. @OfficialRCCSInc

Prepare yourself Philly and Fox Chase! I have arrived 👏🏻👍🏻👊🏻🎉 looking forward to today!

This is an interesting article but in reality it is a hit job on physician's. Sure, physicians can earn nice incomes and most deserve it and more, however, the insurance industry executives are truly highly paid. This is frustrating because everyone knows a Doctor but not everyone is aware of the behind the scenes massive incomes of Health care executives. usatoday.com/story/money/202…

My article following the 2023 presentation with behind the scenes stories from Dr. Siva. 100% control in RCC open.substack.com/pub/proton…

🧑‍⚕️ Two patients. Two different stories. One important question: Which ADC should we choose next in metastatic breast cancer — Sacituzumab Govitecan or Datopotamab Deruxtecan? This infographic compares both ADCs using real clinical scenarios (HR /HER2-negative vs TNBC) based on latest trial data. Save this for your next case discussion 👇

Home alone. Remote work can adversely influence mental health. A new study @ScienceMagazine science.org/doi/10.1126/scie… science.org/doi/10.1126/scie…

#EAU26 Congrats to the FASTRACK teams @_ShankarSiva. SBRT for RCC now has greater prospective data than all other ablative treatments and is a guideline supported SOC. Excited to continue to expand its use through the conduct of well designed clinical trials. Patients want a non-invasive option, but we must continue to generate these excellent results. @ASTRO_org @NCCN @NRGonc @ASCO